Scarica l'app Stockscreener
0.278
13.48%
-0.0433
Dopo l'orario di chiusura:
.29
0.012
+4.32%
Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie
Is Nagreeka Exports Limiteds Business Model Sustainable Long Term - earlytimes.in
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - ts2.tech
Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug By Investing.com - Investing.com Nigeria
Reviva considers a second phase III in schizophrenia - BioWorld MedTech
Dow Gains 100 Points; US Durable Goods Orders Decline In October - Benzinga
Why Did RVPH Stock Crash 50% Today? - Stocktwits
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial By Investing.com - Investing.com Nigeria
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial - Investing.com Australia
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Reviva plans second Phase 3 trial after FDA feedback - TipRanks
Reviva announces regulatory update regarding the development of brilaroxazine for the treatment of schizophrenia - marketscreener.com
Reviva Pharmaceuticals Recover-2 trial projected to cost about $60 million - marketscreener.com
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock maintain growth trajectory2025 Fundamental Recap & Reliable Breakout Forecasts - Улправда
Profit Recap: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionIPO Watch & Smart Swing Trading Techniques - Улправда
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue dividend increasesTrade Performance Summary & Long-Term Safe Investment Plans - Улправда
Volatility Watch: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionTrade Exit Report & Low Risk Entry Point Tips - Улправда
Does Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock trade at a discount to peersPortfolio Value Summary & Risk Controlled Stock Alerts - Улправда
Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionWeekly Investment Report & Capital Efficiency Focused Ideas - Улправда
Will Reviva Pharmaceuticals Holdings Inc. stock attract ESG investorsNew Guidance & Capital Protection Trading Alerts - DonanımHaber
Resistance Check: Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trend2025 Key Highlights & Weekly High Momentum Picks - Улправда
Why retail investors favor Reviva Pharmaceuticals Holdings Inc. stockIPO Watch & Safe Entry Zone Tips - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. stock resist market sell offsMarket Risk Analysis & Daily Volume Surge Trade Alerts - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendWeekly Market Summary & Pattern Based Trade Signal System - Улправда
What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attractive to growth fundsJuly 2025 Momentum & Consistent Return Investment Signals - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. stock sustain institutional interestWeekly Risk Report & Real-Time Market Sentiment Alerts - Улправда
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefit from automation2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Улправда
Block Trades: Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendEarnings Growth Report & Fast Moving Stock Watchlists - Улправда
Profit Recap: Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefit from automationShare Buyback & Weekly Stock Performance Updates - Улправда
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High - Seeking Alpha
Reviva Pharmaceuticals Holdings Inc Stock Analysis and ForecastMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in
683 Capital Management LLC Makes New Investment in Reviva Pharmaceuticals Holdings, Inc. $RVPH - Defense World
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025 - ts2.tech
Stock Traders Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - MarketBeat
Published on: 2025-12-06 19:16:30 - moha.gov.vn
How supply chain issues affect Reviva Pharmaceuticals Holdings Inc. Equity Warrant stockWeekly Investment Summary & Accurate Buy Signal Alerts - Newser
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Are Smart Investors Making the Right Decision? Reviva Pharmaceuticals Holdings Inc (RVPH) - setenews.com
Is RVPH Positioned For NDA Submission In Schizophrenia By 2026? - RTTNews
Reviva Pharmaceuticals Holdings options imply 21.1% move in share price post-earnings - MSN
Reviva’s Schizophrenia Bet Pits Huge Upside Against Harsh Risks - Finimize
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EBIT per share of Reviva Pharmaceuticals Holdings, Inc. Warrant 2020- 25.12.25 on Reviva Pharm – NASDAQ:RVPHW - TradingView
0.36%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):